(Q37340445)

19 August 2017

1 reference

title

AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention (English)

1 reference

19 August 2017

main subject

cervix uterine cancer

1 reference

based on heuristic

inferred from title

human papilloma virus

1 reference

human papillomavirus

29 September 2024

Tino F Schwarz

1

1 reference

19 August 2017

publication date

1 December 2008

1 reference

Expert Review of Vaccines

19 August 2017

published in

1 reference

19 August 2017

volume

7

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

1465-1473

1 reference

The epidemiology of human papillomavirus infections

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

The causal relation between human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Classification of papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

HPV: from infection to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Chapter 2: The burden of HPV-related cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-west Hampshire

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Immune responses to human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Health and economic implications of HPV vaccination in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

Cervical Coinfection with Human Papillomavirus (HPV) Types and Possible Implications for the Prevention of Cervical Cancer by HPV Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

EUROGIN 2007 roadmap—Conclusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1465

10.1586/14760584.7.10.1465

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference